Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia 1Carcinoma, Hepatocellular 1

Interventions

Rituximab 63Cyclophosphamide 57fludarabine phosphate 40fludarabine 37ibrutinib 28Lenalidomide 26Bendamustine Hydrochloride 26Filgrastim 20venetoclax 19obinutuzumab 17Bortezomib 17Peripheral Blood Stem Cell Transplantation 15Etoposide 12Biopsy 12Tacrolimus 11Specimen Handling 11Melphalan 11Interleukin-2 10tanespimycin 9Radiotherapy 9Cytarabine 9aldesleukin 8Whole-Body Irradiation 8Magnetic Resonance Spectroscopy 8idelalisib 7Vorinostat 7Paclitaxel 7Mycophenolic Acid 7Ipilimumab 7Cyclosporine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Lymphocytic, Chronic, B-Cell × CPG-oligonucleotide × Clear all
NCT04995536 2024-04-25

CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL

City of Hope Medical Center

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01035216 2014-12-23

A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

SBI Biotech Co., Ltd.

Phase 1 Terminated
18 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡